Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAV Regimen vs 3+7 in De Novo AML
NCT06697327Enrolling by invitation
- Sponsor
- Anhui Medical University
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Anhui Medical University. Primary endpoint: Overall Response Rate. Started Feb 2025; status: enrolling by invitation.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06697327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697327.